To evaluate the in vivo effects of Sephs1 knockdown on tumor growth and immunotherapy response, we established a subcutaneous B16F10 melanoma model in C57BL/6 J mice, followed by anti-PD-1 treatment. Here, SEPHS1 is linked to melanoma.